Related Experiment Video
Updated: Jun 30, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis
Matthew Burton1, Duncan Marsden1, Dhruv Harish1
1University of Oxford Medical Sciences Division, Oxford, UK.
European Journal of Neurology
|January 29, 2026
Summary
Continuous subcutaneous levodopa/carbidopa infusion significantly reduces OFF-time in Parkinson's disease patients. This novel therapy improves quality of life, though infusion site events are more common.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Parkinson's disease (PD) patients often experience "wearing off" with oral levodopa/carbidopa.
- Higher oral doses increase peak dopamine levels, leading to dyskinesia.
- Continuous subcutaneous infusion offers a novel strategy to reduce OFF-time without peak-dose adverse effects.
Purpose of the Study:
- To evaluate the safety and efficacy of subcutaneous levodopa/carbidopa infusion therapies.
- To compare OFF-time reduction and quality of life scores against oral levodopa/carbidopa.
Main Methods:
- Systematic literature search of MEDLINE, Embase, CENTRAL, and ICTRP up to October 2024.
- Included clinical trials comparing subcutaneous levodopa/foslevodopa infusions to oral levodopa in Parkinson's disease patients.
- Analyzed data from seven studies involving 725 patients.
Main Results:
- Subcutaneous infusion reduced daily OFF-time by 1.98 hours (p=0.0004).
- Improvements observed in health-related quality of life (PDQ-39, p=0.0003) and sleep (PDSS-2, p=0.02).
- Increased treatment-emergent adverse events, primarily infusion site reactions (p=0.04).
Conclusions:
- Subcutaneous infusion therapies significantly reduce OFF-time in Parkinson's disease.
- While quality of life shows statistical improvement, clinical significance is not yet established.
- This method presents a potential alternative for PD patients with motor fluctuations, despite infusion site adverse events.
Related Concept Videos
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...